Avalyn Pharma Inc.
AVLN
$30.71
$1.735.97%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Net Income | -53.51% | ||||
| Total Depreciation and Amortization | 530.00% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | 7,200.00% | ||||
| Change in Net Operating Assets | -135.14% | ||||
| Cash from Operations | -55.08% | ||||
| Capital Expenditure | -3,875.00% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | 129.38% | ||||
| Cash from Investing | 128.14% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | -- | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 725.66% | ||||